



NDA 021797/S-021
NDA 021798/S-023

SUPPLEMENT APPROVAL

Bristol-Myers Squibb Company
Attention: Maria Fradlina-Svirid
TA Lead Mature Products, Global Labeling & Mature Products Strategy
P.O. Box 4000
Princeton, NJ 08543

Dear Ms. Fradlina-Svirid:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received on June 29, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for BARACLUDE (entecavir) Tablets, 0.5 and 1 mg [NDA 021797] and BARACLUDE (entecavir), Oral Solution, 0.05 mg/mL [NDA 021798].

These Prior Approval supplemental new drug applications provide for the following updates to the US Prescribing Information:

- **SECTION 6, ADVERSE REACTIONS:** Adult and pediatric clinical trial adverse reactions information was combined under subsection 6.1, "Clinical Trial Experience" per current best labeling practices
- **SECTION 8, USE IN SPECIFIC POPULATIONS:** Updated to conform to the Pregnancy and Lactation Labeling Rule (PLLR)
- **SECTION 12, CLINICAL PHARMACOLOGY:** Resistance-associated substitutions were reordered in ascending order
- **SECTION 17, PATIENT COUNSELING INFORMATION:** Information was revised per current best labeling practices and the Guidance for Industry on Patient Counseling Information

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Suzanne Strayhorn, Regulatory Project Manager, at (240-402-4247).

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling
Prescribing Information
Patient Package Insert

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

POONAM MISHRA
12/20/2018
on behalf of Debra Birnkrant